4.7 Article

Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 72, Issue 7, Pages 707-717

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.05.049

Keywords

bariatric surgery; body mass index; coronary microvascular dysfunction; obesity; prognosis

Funding

  1. National Institutes of Health [T32 HL094301, T32 HL076136, R01HL132021, K23HL135438]
  2. Gilead Sciences Research Scholars Program in Cardiovascular Disease
  3. Medtronic
  4. Amarin
  5. Amgen
  6. AstraZeneca
  7. Bristol-Myers Squibb
  8. Chiesi
  9. Eisai
  10. Ethicon
  11. Forest Laboratories
  12. Ironwood
  13. Ischemix
  14. Lilly
  15. Pfizer
  16. Roche
  17. Sanofi
  18. Medicines Company
  19. Spectrum Dynamics
  20. General Electric

Ask authors/readers for more resources

BACKGROUND Besides body mass index (BMI), other discriminators of cardiovascular risk are needed in obese patients, who may or may not undergo consideration for bariatric surgery. Coronary microvascular dysfunction (CMD), defined as impaired coronary flow reserve (CFR) in the absence of flow-limiting coronary artery disease, identifies patients at risk for adverse events independently of traditional risk factors. OBJECTIVES The study sought to investigate the relationship among obesity, CMD, and adverse outcomes. METHODS Consecutive patients undergoing evaluation for coronary artery disease with cardiac stress positron emission tomography demonstrating normal perfusion (N = 827) were followed for median 5.6 years for events, including death and hospitalization for myocardial infarction or heart failure. RESULTS An inverted independent J-shaped relationship was observed between BMI and CFR, such that in obese patients CFR decreased linearly with increasing BMI (adjusted p < 0.0001). In adjusted analyses, CFR but not BMI remained independently associated with events (for a 1-U decrease in CFR, adjusted hazard ratio: 1.95; 95% confidence interval: 1.41 to 2.69; p < 0.001; for a 10-U increase in BMI, adjusted hazard ratio: 1.20; 95% confidence interval: 0.95 to 1.50; p = 0.125) and improved model discrimination (C-index 0.71 to 0.74). In obese patients, individuals with impaired CFR demonstrated a higher adjusted rate of events (5.7% vs. 2.6%; p = 0.002), even in those not currently meeting indications for bariatric surgery (6.4% vs. 2.6%; p = 0.04). CONCLUSIONS In patients referred for testing, CMD was independently associated with elevated BMI and adverse outcomes, and was a better discriminator of risk than BMI and traditional risk factors. CFR may facilitate management of obese patients beyond currently used markers of risk. (c) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available